Skip to main content
. 2017 Oct 27;7:14222. doi: 10.1038/s41598-017-14651-y

Figure 2.

Figure 2

(A) Five-year overall survival of patients was 86.8% with well-differentiated tumors, 82.5% with moderately differentiated tumors, and 58.6% with poorly differentiated tumors (p < 0.001). (B) Five-year disease-free survival of patients was 95.1% with well-differentiated tumors, 66.5% with moderately differentiated tumors, and 50.4% with poorly differentiated tumors, p < 0.001; (C) The expression of TTF-1 IHC staining was scored after excluded the advanced stage patients (stage 3&4), Five-year OS was 60.0% in score 1 group, 80.1% in score 2 group, and 86.1% in score 3 TTF-1 group.